Stay informed with expert insights, trends, and best practices in life sciences compliance.
The 3rd Annual Global Compliance Congress for Life Sciences was held by the CBI at the Hilton London Olympia on the 16th & 17th of November, 2016. The conference provided an excellent platform for representatives of life sciences companies to network, share ideas and learn from one another. The ambiance at the conference was high-energy […]
For most pharma companies in the EU, seeking the consent of the HCP’s/HCO’s that they indulge in transactions is the most appropriate means of ensuring compliance with data protection laws when disclosing their spending under the EFPIA disclosure code. Indeed, the Code comes with guidance notes that place special emphasis on pharmaceutical companies seeking consent […]
As the reporting date under the US Sunshine Act approaches, compliance teams are working harder than ever to collect spend records and have them audited and ready to submit to CMS. If anything, the frenzy of resolving system issues, vendor management, and personnel challenges makes it extremely hard for most compliance teams to reach the […]
The 17th Annual Pharma and Medical Device Compliance Congress was held at the Mandarin Hotel in Washington, D.C from the 19th to the 21st of October, 2016. The conference provided an excellent opportunity for senior representatives from the compliance, legal, transparency, legal affairs, commercial operations/marketing, and regulatory affairs industries to network and discuss operational best […]
The 4th Annual Pharma Compliance Europe Congress was held at the Royal Garden Hotel, London, UK, on the 5th and 6th of October, 2016. The conference provided an excellent opportunity for senior representatives from the compliance, legal, transparency, legal affairs, commercial operations/marketing, and regulatory affairs industries to network and discuss operational best practices. Attendees of […]
The largest nursing home pharmacy in the United States of America, based on the number of beds served, Omnicare, has agreed to pay $28.1 million as a means of settling charges of violating the FCA and Anti-kickback statute alleged against it. It was alleged that Omnicare requested and accepted received kickbacks from Abbott Laboratories. In […]